SurVaxM, a cancer vaccine, missed statistical significance for overall survival in patients with newly diagnosed glioblastoma in the SURVIVE trial.
|Articles|January 1, 1995
Oncology NEWS International
- Oncology NEWS International Vol 4 No 1
- Volume 4
- Issue 1
Ethyol Approved for Use in the UK
WEST CONSHOHOCKEN, Pa--The Medicines Control Agency, the regulatory agency for the United Kingdom, has granted a product license for the marketing of Ethyol (amifostine), manufactured by U.S. Bioscience, Inc.
Advertisement
WEST CONSHOHOCKEN, Pa--The Medicines Control Agency, the regulatoryagency for the United Kingdom, has granted a product license forthe marketing of Ethyol (amifostine), manufactured by U.S. Bioscience,Inc.
Ethyol is a selective cytoprotective agent indicated for the reductionof neutropenia-related infection resulting from use of the combinationof cyclophosphamide (Cytoxan, Neosar) and cisplatin (Platinol)in patients with advanced ovarian carcinoma.
Approval of ethyol in this country suffered a set back when anadvisory committee failed to recommend it to the FDA.
Articles in this issue
almost 32 years ago
MDs Fear Managed Care Equals Lower-Quality Carealmost 32 years ago
Dallas Medical Center Launches Umbilical Stem Cell Projectalmost 32 years ago
Navelbine Receives FDA Approval for Advanced Non-Small -Cell Lung Canceralmost 32 years ago
Success of Breast Conserving Surgery Is Not Diminished in Community Settingalmost 32 years ago
Assessment Tools Are Essential to Improve Management of Painalmost 32 years ago
Undertreating Pain Costs Money in the Long Run, Physician Warnsalmost 32 years ago
After 5 Years as Head, Dr. Broder Plans to Resign His Post at NCIalmost 32 years ago
EORTC Endometrial Ca Trial Challenges Findings From GOGalmost 32 years ago
Heterosexual AIDS Cases Up Sharply, But Numbers Remain SmallAdvertisement
Related to this article
Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.
“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.
Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.
Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.
PRV111 eliminated planned surgery in 100% of evaluable patients with non-invasive oral cancer or high-grade dysplasia.
The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.
Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
2
Personalized Vaccines May Have Utility Across All Lung Cancer Stages
3
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
4
Avutometinib/Defactinib Shows Activity in KRAS Wild-Type Recurrent LGSOC
5